Cuorips (TSE:4894) EBITDA Margin %: -2,765.46% (As of Mar. 2026)


TSE:4894 Cuorips Inc TSE:4894
69 GF Score
Price 円3,855.00
GF Value 円28,569.75
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Cuorips EBITDA Margin %?

Cuorips TSE:4894 -1.15% 69 EBITDA Margin % is -2,765.46% as of Mar. 2026. GuruFocus rates TSE:4894 with a GF Score™ of 69/100 and a GF Value™ of 円28,569.75 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Cuorips ranks worse than 70.87% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cuorips's EBITDA for the six months ended in Mar. 2026 was 円-542.8 Mil. Cuorips's Revenue for the six months ended in Mar. 2026 was 円19.6 Mil. Therefore, Cuorips's EBITDA margin for the quarter that ended in Mar. 2026 was -2,765.46%.


Cuorips  (TSE:4894) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cuorips EBITDA Margin % Related Terms


Cuorips EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cuorips's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cuorips EBITDA Margin % Chart

Cuorips Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial -2,015.39 -971.26 -2,243.90 -293.13 -469.46

Cuorips Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only -2,325.55 -4,595.32 -90.17 -235.61 -2,765.46

TSE:4894 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Cuorips's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cuorips EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cuorips's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cuorips's EBITDA Margin % falls into.


TSE:4894
69GF Score
Cuorips Inc TSE:4894
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cuorips EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cuorips's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-996.815/212.332
=-469.46 %

Cuorips's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-542.776/19.627
=-2,765.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -2,765.46% mean?
Cuorips (TSE:4894) has a EBITDA Margin % of -2,765.46% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cuorips and its competitors. According to the industry distribution chart, Cuorips ranks #669 out of 944 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Cuorips' EBITDA Margin % too high?
Cuorips' current EBITDA Margin % is -2,765.46%. Based on the distribution chart, Cuorips ranks #669 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cuorips has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cuorips' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cuorips ranks #669 out of 944 companies for EBITDA Margin %. This places Cuorips in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cuorips and its competitors. Cuorips's current EBITDA Margin % is -2,765.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuorips stock overvalued right now?
Based on GuruFocus' analysis, Cuorips (TSE:4894) is currently considered Possible Value Trap. The stock's GF Value™ is 円28,569.75, compared to a current price of 円3,855.00 — trading 86.5% below its estimated fair value. The current EBITDA Margin % is -2,765.46%. Cuorips' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cuorips (TSE:4894), the current EBITDA Margin % is -2,765.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cuorips (TSE:4894) Overvalued in 2026?

Based on GuruFocus' analysis, Cuorips stock appears to be undervalued. The current stock price of 円3,855.00 is trading 86.5% below its estimated GF Value™ of 円28,569.75. GuruFocus considers Cuorips to be Possible Value Trap.

Key valuation signals for TSE:4894:

  • EBITDA Margin %: -2,765.46%
  • GF Value™: 円28,569.75 vs. price of 円3,855.00 (86.5% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4894 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cuorips Business Description

Address 3-11-5 Nihonbashi-Honcho, 507, Nihonbashi Life Science Building 2, Chuo-ku, Tokyo, JPN, 103-0023
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
69GF Score

Get the complete analysis for TSE:4894

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,855.00
Price
円28,569.75
GF Value